Stock Info Nets

Independent Financial Information Made Easy

Our AI creates

The Best Stock Graphs and Charts

Youtube Subscribe Blog GamificArt

The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.

May 19, 2023 15:13 (London Time)

Vertex Pharmaceuticals

Youtube Subscribe

...

Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9977
MarketCap: 89,651,136,444.0
High: 345.64 Low: 338.12

Open: 341.37 Close: 343.2 Change: 1.83

10 lessons that an AI found about Vertex Pharmaceuticals Stock after reading internet.

This document will help you to evaluate Vertex Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: company, Vertex, Pharmaceuticals, biotech, development, innovative, treatment, …

Concept Map

...

Semantic Network

...

Stock Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.

Today's Summary

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has a market capitalization of $87.877 billion. The company has a strong pipeline of drugs in development, solid fundamentals, and a sound strategy for growth. The biotech industry is projected to grow at a steady pace due to the increasing demand for innovative treatments.

Today's News

Percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. Peer group average for short interest as a percentage of float is 4.62%, which means the company has less short interest. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has a market capitalization of $87.877 billion. Baron Health Care Fund highlighted stocks like Vertex. in the first quarter 2023 investor letter. Vertex Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The business Vertex is a Boston-based biotech company focused on the development and commercialization of therapies for treating cystic fibrosis. Vertex Pharmaceuticals has made 9 investments. In 2021, Vertex announced the acquisition of Semma Therapeutics with an aim to strengthen its position in the field of regenerative medicine and expands its pipeline of innovative therapies for cystic fibrosis. Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating ) last issued its quarterly earnings results on Monday, May 1st. The company had a net margin of 35.40% and a return on equity of 25.06%. Vertex Pharmaceuticals Incorporated is a renowned biopharmaceutical company dedicated to developing treatments for cystic fibrosis and sickle cell disease. The company has a strong pipeline of drugs in development, solid fundamentals, and a sound strategy for growth. Despite some of the risks associated with investing in biotech stocks, many analysts remain bullish on Vertexs prospects. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has been given a “Moderate Buy’ rating by the twenty-three brokerages that are currently covering it. The biotech industry is projected to grow at a steady pace due to the increasing demand for innovative treatments. Vertex Pharmaceuticals is one of the most innovative companies in the pharmaceutical industry when it comes to research and development. The company has dedicated over 20 years of its existence to researching and developing new drugs. Vertex Pharmaceuticals is a leading biotech company that develops and sells drugs for the treatment of serious diseases. The company has a strong pipeline of drugs in development and several already approved by the FDA. The future looks bright for the company, with a strong focus on innovation. Vertex Pharmaceuticals is a biotechnology company that specializes in discovering and developing innovative treatments for serious diseases. The company has seen impressive growth over the years, with a compound annual growth rate (CAGR) of over 30%. Vertex Pharmaceuticals is a biotech company that focuses on the development of innovative medicines for serious diseases. The company has made remarkable progress in the treatment of cystic fibrosis, a life-threatening genetic disease. In 2020, the company reported an annual revenue of $6.2 billion. Vertex Pharmaceuticals Incorporated has been a strong performer in the biotech industry. The company has consistent revenue growth and significant investments in research and development. However, the companys net income has been somewhat inconsistent.

Stock Profile

"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."

Keywords

How much time have you spent trying to decide whether investing in Vertex Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: company, Vertex, Pharmaceuticals, biotech, development, innovative, treatment, and the most common words in the summary are: vertex, pharmaceutical, stock, company, vrtx, market, news, . One of the sentences in the summary was: The biotech industry is projected to grow at a steady pace due to the increasing demand for innovative treatments.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #pharmaceutical #stock #company #vrtx #market #news.

Read more →

Related Results

...
March 09, 2024 19:01 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated (VRTX) stock has fallen -2.15% while the S&P 500 has risen 0.2% as of 2:55 PM on Monday, Mar 4. The company is e…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.875
MarketCap: 106,833,529,619.0
High: 416.25 Low: 410.95

Open: 412.34 Close: 413.59 Change: 1.25

Read more →
...
February 22, 2024 2:49 (London Time)

Vertex Pharmaceuticals

20 analysts share their evaluations of Vertex Pharmaceuticals (NASDAQ:VRTX), revealing diverse outlooks from bullish to bearish. That average rating…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.7712
MarketCap: 108,393,708,828.0
High: 424.0 Low: 414.8

Open: 421.77 Close: 419.63 Change: -2.14

Read more →
...
February 12, 2024 0:26 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stock closed at $423.06 per share on February 8, 2024. One-month return of Vertex pharmaceuticals …
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9871
MarketCap: 108,976,795,345.0
High: 425.96 Low: 419.51

Open: 425.96 Close: 422.91 Change: -3.05

Read more →
...
January 03, 2024 5:34 (London Time)

Vertex Pharmaceuticals

Shares of Vertex Pharmaceuticals Inc. (VRTX) are up today. The stock price of VRTX is 40688 while the stock price is 406-8088. The company engages i…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9136
MarketCap: 105,879,443,473.0
High: 412.26 Low: 403.43

Open: 405.0 Close: 410.91 Change: 5.91

Read more →
...
November 28, 2023 9:42 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated (VRTX) stock is down -0.73% while the S&P 500 has gained 0.23% as of 2:40 PM on Wednesday, Nov 22. Sell-side ana…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9287
MarketCap: 90,238,074,204.0
High: 354.45 Low: 349.16

Open: 353.95 Close: 350.19 Change: -3.76

Read more →
...
November 13, 2023 19:56 (London Time)

Vertex Pharmaceuticals

Argus has published its latest Portfolio Selector, which features its popular Focus List. Vertex Pharmaceuticals missed Wall Street estimates for th…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.5106
MarketCap: 96,283,321,701.0
High: 378.46 Low: 371.75

Open: 373.16 Close: 378.35 Change: 5.19

Read more →
...
November 02, 2023 13:14 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals and CRISPR Therapeutics are vying for FDA approval of a gene editing drug called Exa-Cel. If approved by the FDA, Vertex woul…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.8074
MarketCap: 95,322,158,023.0
High: 370.71 Low: 363.22

Open: 364.95 Close: 369.33 Change: 4.38

Read more →
...
October 12, 2023 9:32 (London Time)

Vertex Pharmaceuticals

Vertex develops therapies to address cystic fibrosis and other diseases. The biotechnology company is rated a Buy.
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9578
MarketCap: 94,269,131,178.0
High: 365.27 Low: 359.14

Open: 361.46 Close: 365.25 Change: 3.79

Read more →
...
August 19, 2023 12:53 (London Time)

Vertex Pharmaceuticals

Analysts estimate an earnings increase this quarter of $0.33 per share, an increase next quarter of$0.14 per share. The current share price of VRTX …
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9826
MarketCap: 88,996,254,108.0
High: 347.44 Low: 342.42

Open: 343.4 Close: 344.82 Change: 1.42

Read more →
...
August 02, 2023 2:34 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals 2q profit up on higher cystic fibrosis drug revenue. CEO Reshma Kewalramani sold 7,828 shares of the businesss stock in a tra…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.979
MarketCap: 89,560,993,384.0
High: 352.47 Low: 345.69

Open: 351.42 Close: 347.74 Change: -3.68

Read more →
...
June 14, 2023 19:32 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX) stock is trading at $343.16 as of 3:23 PM on Tuesday, Jun 13, a gain of $2.56, or 0.75% from the previous closing pric…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9552
MarketCap: 88,108,402,360.0
High: 342.63 Low: 338.2

Open: 342.63 Close: 340.54 Change: -2.09

Read more →
...
May 25, 2023 21:26 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX) develops small molecule drugs for serious diseases. Firm recently partnered with Stablix Pharmaceuticals on April 4, 2…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9846
MarketCap: 89,651,136,444.0
High: 333.98 Low: 327.59

Open: 330.92 Close: 332.63 Change: 1.71

Read more →
...
May 10, 2023 7:53 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day. Management will present at Cowens 43rd Annual Health Care Conferenc…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9916
MarketCap: 89,651,136,444.0
High: 346.49 Low: 342.66

Open: 343.29 Close: 344.83 Change: 1.54

Read more →
...
February 22, 2024 11:58 (London Time)

Vertex Pharmaceuticals

20 analysts share their evaluations of Vertex Pharmaceuticals (NASDAQ:VRTX), revealing diverse outlooks from bullish to bearish. Average price targe…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.6486
MarketCap: 108,393,708,828.0
High: 424.0 Low: 414.8

Open: 421.77 Close: 419.63 Change: -2.14

Read more →
...
February 14, 2024 16:56 (London Time)

Vertex Pharmaceuticals

Average price target for Vertex Pharmaceuticals comes to $447.00. The current share price is $416.02 USD today. There is no upcoming split for the c…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.3542
MarketCap: 107,201,358,207.0
High: 420.45 Low: 415.01

Open: 418.38 Close: 415.51 Change: -2.87

Read more →
...
January 08, 2024 1:33 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc. announced program updates, including strong performance in cystic fibrosis and pipeline acceleration. A phase 1/2 trial …
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.743
MarketCap: 107,325,046,136.0
High: 418.52 Low: 414.42

Open: 415.01 Close: 416.5 Change: 1.49

Read more →
...
December 16, 2023 8:26 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals has on average historically risen by 31.3% based on the past 32 years of stock performance. The current trend is considered s…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.8225
MarketCap: 105,925,826,446.0
High: 411.6 Low: 400.51

Open: 408.16 Close: 410.68 Change: 2.52

Read more →
...
November 25, 2023 16:13 (London Time)

Vertex Pharmaceuticals

Wall Street analysts predict that Vertex Pharmaceuticals s share price could reach $380.77 by Nov 22, 2024. Wall Street analyst estimates that VRTXs…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9153
MarketCap: 90,972,471,279.0
High: 355.41 Low: 350.44

Open: 354.95 Close: 353.04 Change: -1.91

Read more →
...
November 06, 2023 13:10 (London Time)

Vertex Pharmaceuticals

Morgan: Exagamglogene Autotemcel (exa) will report its third quarter 2023 financial results. Seven abstracts have been accepted for presentation at …
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.8885
MarketCap: 97,095,269,403.0
High: 381.0 Low: 375.85

Open: 379.64 Close: 376.2 Change: -3.44

Read more →
...
October 30, 2023 21:16 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals is 95.08% away from the 52-week high. The 73 analysts offering price forecasts for the company have a median target of 328.47…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.8779
MarketCap: 91,721,735,354.0
High: 358.88 Low: 355.58

Open: 357.15 Close: 357.45 Change: 0.3

Read more →
...
September 17, 2023 18:33 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc. rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex. Washington Trust Bank grew …
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9723
MarketCap: 90,049,280,953.0
High: 352.75 Low: 348.07

Open: 351.26 Close: 348.9 Change: -2.36

Read more →
...
August 03, 2023 5:09 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals raises full-year sales forecast on Tuesday, banking on strong demand for cystic fibrosis treatment strength. CEO Reshma Kewal…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9477
MarketCap: 89,560,993,384.0
High: 360.98 Low: 344.24

Open: 350.0 Close: 358.4 Change: 8.4

Read more →
...
June 29, 2023 15:08 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc. develops small molecule drugs for serious diseases. The 130,000ft² site will be run by Lonza and will create 300 jobs. T…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.967
MarketCap: 90,372,280,924.0
High: 351.86 Low: 348.07

Open: 349.91 Close: 350.87 Change: 0.96

Read more →
...
May 30, 2023 22:09 (London Time)

Vertex Pharmaceuticals

15 analysts rated Vertex Pharmaceuticals over the past 3 months. 15 analysts have an average price target of $367.13 versus the current price of Ver…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.8537
MarketCap: 89,651,136,444.0
High: 330.07 Low: 321.61

Open: 329.82 Close: 325.3 Change: -4.52

Read more →
...
May 19, 2023 15:13 (London Time)

Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has a market capitalization of $87.877 billion. The company has a strong pipeline of drugs in deve…
Sector: Biotechnology
Ticker: VRTX
Sentiment: 0.9977
MarketCap: 89,651,136,444.0
High: 345.64 Low: 338.12

Open: 341.37 Close: 343.2 Change: 1.83

Read more →